Insider Trading activities of Bellerophon Therapeutics, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bellerophon Therapeutics, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Bellerophon Therapeutics, Inc. since year 2005. Table 2 shows the detailed insider transactions of Bellerophon Therapeutics, Inc. since 2005. The reporting company's ticker symbol is BLPH. The reporting company's CIK number is 1600132.
The total value of stock buying since 2005 is $53,129,000.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Bellerophon Therapeutics, Inc. (BLPH).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-09 715,394 $0 0 $0 0 $0
2016-12 20,000 $11,200 0 $0 0 $0
2016-11 1,142,857 $0 0 $0 0 $0
2016-05 5,000 $6,840 0 $0 0 $0
2015-12 20,300 $55,740 0 $0 0 $0
2015-08 5,000 $27,375 0 $0 0 $0
2015-05 6,272 $54,301 0 $0 0 $0
2015-02 4,414,462 $52,973,544 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Bellerophon Therapeutics, Inc. insiders (BLPH)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-09-29 Amin Naseem Buy 456,432 .00 0
2017-09-29 Luehring Jens Buy 10,000 .00 0
2017-09-29 Peacock Jonathan M Buy 248,962 .00 0
2016-12-09 Luehring Jens Buy 20,000 .56 11,200
2016-11-29 Amin Naseem Buy 714,285 .00 0
2016-11-29 Tenenbaum Fabian (Chief Executive Officer) Buy 142,857 .00 0
2016-11-29 Peacock Jonathan M Buy 285,715 .00 0
2016-05-17 Peacock Jonathan M (President and CEO) Buy 5,000 1.37 6,840
2015-12-16 Peacock Jonathan M (President and CEO) Buy 12,800 2.76 35,340
2015-12-15 Peacock Jonathan M (President and CEO) Buy 7,500 2.72 20,400
2015-08-19 Peacock Jonathan M (President and CEO) Buy 5,000 5.47 27,375
2015-05-20 Peacock Jonathan M (President and CEO) Buy 5,560 8.69 48,321
2015-05-20 Meglasson Martin (Chief Scientific Officer) Buy 712 8.40 5,980
2015-02-19 Holt Matthew S. (Director) Buy 1,070,166 12.00 12,841,992
2015-02-19 Luehring Jens (Director) Buy 358,916 12.00 4,306,992
2015-02-19 Naidu Manesh (Chief Business Officer) Buy 1,500 12.00 18,000
2015-02-19 Heyrman Reinilde (Chief Clinical Dev. Officer) Buy 1,500 12.00 18,000
2015-02-19 Weinstein Adam (Director) Buy 1,070,166 12.00 12,841,992
2015-02-19 Linde North America, Inc. (10% Owner) Buy 358,916 12.00 4,306,992
2015-02-19 Tasse Daniel (Director) Buy 25,000 12.00 300,000
2015-02-19 Peacock Jonathan M (President and CEO) Buy 20,800 12.00 249,600
2015-02-19 Meglasson Martin (Chief Scientific Officer) Buy 12,000 12.00 144,000
2015-02-19 Bybee Clinton (10% Owner) Buy 212,666 12.00 2,551,992
2015-02-19 Nelsen Robert (Director) Buy 212,666 12.00 2,551,992
2015-02-19 Klinsky Steven B (10% Owner) Buy 1,070,166 12.00 12,841,992

Insider trading activities including stock purchases, stock sales, and option exercises of BLPH listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Bellerophon Therapeutics, Inc. (symbol BLPH, CIK number 1600132) see the Securities and Exchange Commission (SEC) website.